GHRP-6 + Hgh Frag

Snapshot: Gonadorelin is a synthetic version of gonadotropin-releasing hormone (GnRH), a key signalling molecule produced in the hypothalamus [1]. It triggers the pituitary to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH) [2]. Clinically, it is used to assess hypothalamic-pituitary function and to induce ovulation in select cases [2]. What Is Gonadorelin Peptide? Gonadorelin peptide is a low-weight, synthetic analogue structurally identical to the body’s endogenous GnRH released by the hypothalamus [1]. It acts as a central regulator of the hypothalamic-pituitary-gonadal axis, stimulating pituitary release of LH and FSH to control reproduction, sex hormone production, and fertility [1]. It binds to LHRH receptors on pituitary gonadotroph cells to stimulate the release of LH and FSH; with continuous exposure, these receptors become desensitized [3]. Clinically, it is used to assess hypothalamic–pituitary function and in select cases of hypothalamic amenorrhea [3]. It is listed as a prohibited substance by the World Anti-Doping Agency (WADA) and can be detected in urine [4]. Gonadorelin peptide effects and uses Gonadorelin has broad clinical applications across reproductive medicine, endocrinology, and gynecology [5]. By providing direct stimulation to the hypothalamic-pituitary-gonadal axis, it has shown benefits for restoring physiological hormone signalling and modulating it for diagnostic or therapeutic purposes [5]. Gonadorelin has been clinically explored to induce ovulation and support fertility interventions, assess endocrine function, manage hormone-sensitive conditions, and treat gynecologic disorders, including endometriosis and uterine fibroids [5]. It has also been studied for contraceptive use and for protecting ovarian function during chemotherapy [6]. Ovulation induction Evidence suggests gonadorelin can support ovulation through restoration or modulation of the normal hypothalamic-pituitary axis signalling [7]. By mimicking endogenous GnRH, gonadorelin can normalize LH and FSH release, re-establish physiologic GnRH pulsatility, and promote ovulatory function in hyperandrogenic disorders and gonadotropin imbalance [1]. Experimental models demonstrate meaningful ovulation rates with gonadorelin compared to controls, supporting its role as an effective ovulation-induction agent [8]. It works via triggering a pituitary LH surge that promotes dominant follicle ovulation and corpus luteum formation [8]. In one animal model, gonadorelin increased sex steroid levels and induced ovulation in 67% of treated females, while no control subjects ovulated [9]. Hormonal Disorder Treatments Gonadorelin modulates the hypothalamic-pituitary-gonadal axis to regulate sex hormone signalling across a range of conditions [10]. When administered repeatedly, it can induce a reversible pituitary desensitization, causing temporary suppression of gonadotropin signalling to sex organs [10]. Clinically, gonadorelin has shown benefits in: Hormone-sensitive prostate cancer [11]. Premenopausal hormone-sensitive breast cancer, where suppression of ovarian steroid production is therapeutically beneficial [12]. Hormonal dysregulation where an induced controlled, reversible hypogonadotropism in conditions of hormone dysregulation can allow endocrine signalling to stabilize [13]. For example, it can help manage precocious puberty to suppress premature activation of the reproductive axis [14]. Managing endometriosis and uterine fibroid size, where the peptide can produce temporary remission of the diseases [14]. Severe, recurrent acute porphyria where prophylactic use of gonadorelin analogues reduced attack frequency in approximately half of treatment courses [15]. Animal studies also show benefits. A large field trial involving dairy cows with cystic ovarian disease reported resolution rates exceeding 90% after a single treatment, regardless of timing postpartum, highlighting the reliability of its hormonal action [16]. Boosting Success Rates of Fertility Treatments Gonadorelin is thought to improve fertility treatment outcomes by stabilizing pituitary signalling during controlled ovarian stimulation [17]. By suppressing erratic or premature LH release, gonadorelin helps to prevent premature ovulation and hormone fluctuations that can disrupt cycle timing [17]. This control can increase the proportion of adequate stimulation cycles, reduce cycle cancellation, and may allow greater flexibility in scheduling stimulation and optimizing IVF protocols. Animal models have found that adding gonadorelin can support pregnancy outcomes. A large cattle study in Brazil found that administering gonadorelin at the time of fixed-time embryo transfer significantly improved conception rates at both 30 and 60 days of gestation compared with untreated controls [17]. Treated animals also showed reduced pregnancy loss, indicating that GnRH analogue use can enhance embryo transfer success, even under less favorable conditions [17]. Gonadorelin side effects There are several known side effects of gonadorelin peptide, with many largely related to predictable, reversible hypoestrogenic states. The most common are mild, including abdominal discomfort, short-lasting flushing, headaches, light-headedness, and nausea [18]. Following repeated doses, there have been reports in the literature of difficulty breathing, continuous flushing, and rapid heart rate, although they are rare [18]. Injection site reactions can occur, as well as hormonal side effects from estrogen depletion, including hot flashes, vaginal dryness, and reversible trabecular bone resorption [18, 2]. References 1 Torrini, F., Scarano, S., Palladino, P. and Minunni, M. (2023) Advances and perspectives in the analytical technology for small peptide hormones analysis: A glimpse to gonadorelin. J. Pharm. Biomed. Anal., Elsevier BV 228, 115312 2 Chrisp, P. and Goa, K. L. (1990) Nafarelin: A review of its pharmacodynamic and pharmacokinetic properties, and clinical potential in sex hormone-related conditions. Drugs, Springer Nature 39, 523–551 3 National Cancer Institute. (2020, February 7) Recombinant Gonadorelin. Definitions, Qeios https://doi.org/10.32388/9g8tac 4 The Prohibited List. World Anti Doping Agency https://www.wada-ama.org/en/prohibited-list 5 Conn, P. M. and Crowley, W. F., Jr. (1994) Gonadotropin-releasing hormone and its analogs. Annu. Rev. Med., Annual Reviews 45, 391–405 6 Lambertini, M., Moore, H. C. F., Leonard, R. C. F., Loibl, S., Munster, P., Bruzzone, M., et al. (2018) Gonadotropin-releasing hormone agonists during chemotherapy for preservation of ovarian function and fertility in premenopausal patients with early breast cancer: A systematic review and meta-analysis of individual patient-level data. J. Clin. Oncol., J Clin Oncol 36, 1981–1990 7 Picard-Hagen, N., Lhermie, G., Florentin, S., Merle, D., Frein, P. and Gayrard, V. (2015) Effect of gonadorelin, lecirelin, and buserelin on LH surge, ovulation, and progesterone in cattle. Theriogenology, Elsevier BV 84, 177–183 8 Lima, F. S., Ayres, H., Favoreto, M. G., Bisinotto, R. S., Greco, L. F., Ribeiro, E. S., et al. (2011) Effects of gonadotropin-releasing hormone at initiation of the 5-d timed artificial insemination (AI) program and timing of induction of ovulation relative to AI on ovarian dynamics and fertility of dairy heifers. J. Dairy Sci., American Dairy Science Association 94, 4997–5004 9 Oliveira, R. G. de S., de Morais, I. S., Paixão, R. V., Bandeira, I. C., Duncan, W. L. P. and O’Sullivan, F. L. de A. (2025) Effects of gonadorelin on gonadotropin expression, plasma sex steroid concentrations and ovarian follicle dynamics in mature tambaqui (Colossoma macropomum). Comp. Biochem. Physiol. B Biochem. Mol. Biol., Elsevier BV 279, 111126 10 Wang, X., Zhang, Z. X., Chen, J., Fu, D., Du, M., Chen, Y., et al. (2025) Efficacy and safety of pulsatile GnRH pump therapy in male infants with congenital hypogonadotropic hypogonadism. Endocr. Connect., Bioscientifica Ltd 14 https://doi.org/10.1530/EC-24-0655 11 Barrett, R., Barrett, R., Dhar, K. and Birch, B. (2021) Gonadorelins adherence in prostate cancer: A time-series analysis of England’s national prescriptions during the COVID-19 pandemic (from Jan 2019 to Oct 2020). BJUI Compass, Wiley 2, 419–427 12 Huerta-Reyes, M., Maya-Núñez, G., Pérez-Solis, M. A., López-Muñoz, E., Guillén, N., Olivo-Marin, J.-C., et al. (2019) Treatment of breast cancer with gonadotropin-releasing hormone analogs. Front. Oncol., Frontiers Media SA 9, 943 13 Shao W.-M., Bai W.-J., Chen Y.-M., Liu L. and Wang Y.-J. (2014) Micropump infusion of gonadorelin in the treatment of hypogonadotropic hypogonadism in patients with pituitary stalk interruption syndrome: cases analysis and literature review. Beijing Da Xue Xue Bao, Beijing Da Xue Xue Bao Yi Xue Ban 46, 642–645 14 Foye, W. O. (2008) Foye’s principles of medicinal chemistry, Lippincott williams & wilkins 15 Schulenburg-Brand, D., Gardiner, T., Guppy, S., Rees, D. C., Stein, P., Barth, J., et al. (2017) An audit of the use of gonadorelin analogues to prevent recurrent acute symptoms in patients with acute porphyria in the United Kingdom. JIMD Rep., Springer Berlin Heidelberg 36, 99–107 16 Hooijer, G. A., Frankena, K., Valks, M. M. and Schuring, M. (1999) Treatment of cystic ovarian disease in dairy cows with gonadotrophin-releasing hormone: a field study. Vet. Q., Informa UK Limited 21, 33–37 17 Defensor, M. L., Faria, A. C. F., Marques, F. L. A., Cadima, G. P., Mafra, M. O. and Santos, R. M. dos. (2021, September 13) Effect of treatment with gonadoreline at the embryo transfer on pregnancy outcomes in bovine. Research Square https://doi.org/10.21203/rs.3.rs-765941/v1 18 (2024, February 15) Gonadorelin: Indications, Side Effects, Warnings. Drugs.com https://www.drugs.com/cdi/gonadorelin.html

Snapshot: Hexarelin is a synthetic hexapeptide and potent growth hormone secretagogue that selectively activates GHS-R (ghrelin) receptors to simulate endogenous, pulsatile GH release. Preclinical studies suggest potential roles in cardiomyocyte protection under ischemic stress, metabolic and lipid-regulating pathways, skeletal muscle mass preservation, and organ-protective stress-response signalling. What Is Hexarelin? Hexarelin (examorelin) is a synthetic hexapeptide (His-D-2-Methyl-Trp-Ala-Trp-D-Phe-Lys-NH2) belonging to the group of growth hormone secretagogues (GHS) [1]. It was developed as a selective GHS-R ghrelin receptor agonist to enhance the body’s natural growth-hormone output, rather than replace it with exogenous hormone [1]. Through high-affinity receptor binding in the hypothalamus and pituitary, hexarelin activates G-protein coupled signalling, intracellular calcium mobilization, and cAMP-linked pathways that support pulsatile GH release patterns [2]. The peptide incorporates non-natural amino acids including D-2-methyltryptophan, D-phenylalanine, and lysine amide, increasing resistance to enzymatic degradation and improving its pharmacokinetic stability [3]. It is metabolized in the liver with renal elimination and remains analytically detectable for up to 8 hours post-administration [3]. Hexarelin Peptide Benefits In addition to GH signalling, hexarelin is widely used in experimental and preclinical research to study cardiometabolic stress responses, intracellular calcium regulation, oxidative stress and inflammatory markers, and survival-associated pathways in cardiac and skeletal muscle models. Cardiovascular Protection Hexarelin activates two key receptors found directly in cardiac muscle and blood vessels, GHSR-1a receptor and CD36 [4]. Because these receptors are present in heart muscle cells themselves, many of hexarelin’s effects appear to come from local, tissue-level signalling inside the heart, rather than through increasing circulating growth hormone [4]. In many experimental models, hexarelin enhanced myocardial contractility. Hexarelin has been shown to improve intracellular calcium handling and activates downstream kinase pathway (including protein kinase C signalling), resulting in a positive inotropic effect without increasing heart rate or imposing excess hemodynamic load [4]. Hexarelin has also demonstrated cytoprotective effects under stress conditions, including heart failure, ischemia, and toxin exposure [4]. It attenuates cardiomyocyte and endothelial apoptosis, reduces DNA fragmentation, and promotes survival-associated signalling, thereby supporting the preservation of myocardial tissue over time [4]. In ischemic-reperfusion models, hexarelin reduced infarct size and improved recovery of post-ischemic ventricular performance, and heart conduction stabilization [4]. Chronic cardiovascular stress is a driver of fibrotic remodelling, and hexarelin seems to mitigate this process by downregulating collagen I and III expression, reducing profibrotic signaling, and enhancing metalloprotease activity – changes consistent with reduced myocardial stiffness and improved diastolic function [4]. Combined, these findings suggest hexarelin may help the heart contract more efficiently, withstand stress, and recover more efficiently following injury, with actions driven largely by its direct interaction with cardiac receptors [4]. Body Composition & Metabolic Health Hexarelin and related growth-hormone secretagogues have been investigated for their effects on lipid metabolism, insulin-resistance markers, skeletal muscle mass preservation, and cachexia-induced signalling pathways. In a study of healthy older adults, those with higher total fat mass, body fat percentage, BMI or bodyweight showed a smaller growth hormone response after a single dose of hexarelin [5]. Fat mass was the strongest predictor of response, while gender’s predictive effect was not significant once body composition was adjusted [5]. This trend occurred across a continuum, with even moderate increases in body fat linked to reduced GH response. This suggests higher adiposity can blunt GH-sectretagogue signalling [5]. Beyond hormone responsiveness, preclinical research indicates hexarelin may support metabolic resilience and cellular protection [6]. In models of chemically induced pancreatic beta-cell damage, hexarelin reduced mitochondrial injury, oxidative stress, and activation of cell-death pathways, while preserving beta-cell structure and insulin levels [6]. These findings suggest a potential role in protecting beta-cell mass under oxidative and metabolic stress conditions [6]. Additional animal models have shown improvements in glucose and insulin tolerance, lowered liver and plasma triglycerides, and enhanced fat-cell differentiation and lipid handling [7]. These improvements occurred without increases in total body weight and were accompanied by a shift toward lower fat mass and higher lean mass, despite increased food intake [7]. These effects may relate, in part, to CD36-linked lipid metabolism pathways [7]. Organ Protection Research across cardiac, metabolic, and skeletal muscle systems indicates that hexarelin may exert organ-protective effects. It is thought these effects occur through activation of survival- and stress-response pathways, modulation of fibrosis and remodelling signals, stabilization of intracellular calcium dynamics, and protection of mitochondrial function under metabolic or toxic stress [8, 9, 10, 6]. These effects are currently described within experimental frameworks and mechanistic investigations, rather than clinical outcome studies. 1 Carpino, P. A. (2002) Recent developments in ghrelin receptor (GHS-R1a) agonists and antagonists. Expert Opin. Ther. Pat., Informa Healthcare 12, 1599–1618 2 Imbimbo, B. P., Mant, T., Edwards, M., Amin, D., Dalton, N., Boutignon, F., et al. (1994) Growth hormone-releasing activity of hexarelin in humans. A dose-response study. Eur. J. Clin. Pharmacol., Springer 46, 421–425 3 Ghigo, E., Arvat, E., Gianotti, L., Imbimbo, B. P., Lenaerts, V., Deghenghi, R., et al. (1994) Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration in man. J. Clin. Endocrinol. Metab., The Endocrine Society 78, 693–698 4 Mao, Y., Tokudome, T. and Kishimoto, I. (2014) The cardiovascular action of hexarelin. J. Geriatr. Cardiol. 11, 253–258 5 Rahim, A., O’Neill, P. and Shalet, S. M. (1998) The effect of body composition on hexarelin-induced growth hormone release in normal elderly subjects. Clin. Endocrinol. (Oxf.), Wiley 49, 659–664 6 Zhao, Y., Zhang, X., Chen, J., Lin, C., Shao, R., Yan, C., et al. (2016) Hexarelin protects rodent pancreatic Β-cells function from cytotoxic effects of streptozotocin involving mitochondrial signalling pathways in vivo and in vitro. PLoS One, Public Library of Science (PLoS) 11, e0149730 7 Mosa, R., Huang, L., Wu, Y., Fung, C., Mallawakankanamalage, O., LeRoith, D., et al. (2017) Hexarelin, a growth hormone secretagogue, improves lipid metabolic aberrations in nonobese insulin-resistant male MKR mice. Endocrinology, Endocrinology 158, 3174–3187 8 Guan, C., Li, C., Shen, X., Yang, C., Liu, Z., Zhang, N., et al. (2023) Hexarelin alleviates apoptosis on ischemic acute kidney injury via MDM2/p53 pathway. Eur. J. Med. Res., Springer Science and Business Media LLC 28, 344 9 Rossoni, G., De Gennaro Colonna, V., Bernareggi, M., Polvani, G. L., Müller, E. E. and Berti, F. (1998) Protectant activity of hexarelin or growth hormone against postischemic ventricular dysfunction in hearts from aged rats. J. Cardiovasc. Pharmacol., Ovid Technologies (Wolters Kluwer Health) 32, 260–265 10 Zambelli, V., Rizzi, L., Delvecchio, P., Bresciani, E., Rezoagli, E., Molteni, L., et al. (2021) Hexarelin modulates lung mechanics, inflammation, and fibrosis in acute lung injury. Drug Target Insights, Aboutscience Srl 15, 26–33

What is LGF-LR3 peptide? Insulin-like Growth Factor 1 Long Arg3 (IGF-1 LR3) is a synthetic analog of human IGF-1, a naturally occurring peptide hormone that plays a critical role in growth, repair, and metabolic regulation. Structurally, IGF-1 LR3 consists of 83 amino acids, whereas native IGF-1 has 70 amino acids. IGF-1 LR3 has two additional key modifications: the substitution of arginine for glutamic acid at position 3, and the addition of a 13–amino acid extension at the N-terminus [1]. LGF These alterations significantly extend its half-life and reduce its binding affinity to IGF-binding proteins, enhancing its biological availability in circulation. LGF-LR3 benefits Anabolic benefits By activating IGF-1 receptors, LGF-LR3 can initiate various intracellular signaling pathways, including PI3K/Akt/mTOR and MAPK/ERK, which are central to [2, 3]: Cell proliferation Differentiation Protein synthesis, including in skeletal muscles IGF-1 stimulates satellite cell activation and differentiation, key processes for muscle hypertrophy and repair following injury or intensive exercise [4]. However, these effects have yet to be studied in LGF-LR3 specifically. LGF-LR3 enhances amino acid uptake, which can theoretically increase protein synthesis, and promotes the fusion of myoblasts into mature muscle fibers, contributing to muscle growth. An animal study examined whether infusion of IGF-1 LR3 could improve growth and metabolic parameters in fetuses affected by placental insufficiency and fetal growth restriction (FGR) [5]. Fourteen fetal sheep were divided into two groups: one receiving IGF-1 LR3 infusion (1.17  μg/kg·h) and a control group receiving only the vehicle over one week. Glucose-stimulated insulin secretion (GSIS) tests were performed at the end of the treatment period to assess β-cell function. Results showed: No significant difference in body weight between IGF-1 LR3-treated and control fetuses after one week of treatment. Baseline and post-treatment plasma insulin, glucose, and GSIS remained unchanged. IGF-1 LR3 treatment led to a significant decrease in circulating amino acid concentrations (p = 0.02). IGF-1 LR3 did not enhance fetal growth or insulin dynamics in growth-restricted fetuses under these experimental conditions. The observed decline in amino acid levels suggested possible increased tissue uptake or utilization, suggesting higher metabolic demand without adequate substrate availability. Supplemental amino acids, glucose, or oxygenation may be necessary to optimize IGF-1-mediated growth responses in FGR scenarios. Brain health and cognition IGF-1 LR3 has drawn increasing interest for its neuroprotective and cognitive-enhancing potential, reflecting the broader role of IGF signaling in the central nervous system (CNS). Endogenous IGF-1 is widely expressed in both neurons and glial cells [6]. A study in 5XFAD mice (a transgenic model that rapidly develops amyloid-β (Aβ) pathology of Alzheimer’s disease) evaluated whether intranasal LR3-IGF-1 could mitigate cognitive decline and reduce AD-related pathology [7]. Wild-type and 5XFAD mice were treated intranasally with LR3-IGF-1 or vehicle solution from 3 to 10 months of age. Results showed that LR3-IGF-1 treatment: Did not significantly improve cognitive performance in 5XFAD mice despite long-term treatment. Altered Aβ plaque morphology by reducing filamentous (toxic) plaques and increasing inert, less harmful forms. Enhanced Aβ1–42 uptake by microglia and upregulated genes related to actin remodeling and endocytosis, indicating improved microglial clearance function. Improved body composition, suggesting systemic anabolic activity. Although LR3-IGF-1 did not prevent cognitive decline, it produced measurable benefits in amyloid plaque remodeling and microglial function, implying a partial neuroprotective effect at the cellular level. While human data remain limited, these findings point to IGF-1 LR3 as a promising anti-aging agent for the brain. Energy metabolism and glucose regulation IGF-1 LR3 plays a pivotal role in energy balance and glucose metabolism, closely mirroring the physiological actions of insulin. An animal study explored how short-term exposure to IGF-1 LR3 affects insulin secretion dynamics [8]. Ten fetal sheep were infused intravenously for 90 minutes with either IGF-1 LR3 (n = 5) or vehicle control (n = 5). Results showed that: Plasma insulin levels dropped approximately 66% during IGF-1 LR3 infusion (p < 0.0001). Isolated islets from IGF-1 LR3-treated fetuses displayed normal insulin release when exposed to glucose or potassium chloride, indicating recovery of β-cell function. Acute IGF-1 LR3 infusion transiently suppressed insulin secretion in vivo, without damaging β-cells. This suggests that the inhibitory effects are reversible and may have therapeutic use for intrauterine growth restriction (IUGR) or metabolic modulation during development.